Current Strategies and Challenges for Purification of Cardiomyocytes Derived from Human Pluripotent Stem Cells

• Type of Material: Article
• Authors: Kiwon Ban, City University of Hong Kong; Seongho Bae, Emory University; Young-sup Yoon, Emory University
• Language: English
• Date: 2017-01-01
• Publisher: Ivyspring International Publisher
• Publication Version: Final Published Version
• Copyright Statement: Copyright © Ivyspring International Publisher
• License: Creative Commons Attribution-NonCommercial 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.7150/thno.19427
• Title of Journal or Parent Work: Theranostics
• ISSN: 1838-7640
• Volume: 7
• Issue: 7
• Start Page: 2067
• End Page: 2077
• Grant/Funding Information: This work was also supported by a CityU Start-up Grant (No 7200492), a CityU Research Project (No 9610355), and a Georgia Immuno Engineering Consortium through funding from Georgia Institute of Technology, Emory University, and the Georgia Research Alliance.; This work was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIP) (No 2015M3A9C6031514), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C2782, HI16C2211) and grants from NHLBI (R01HL127759, R01HL129511), NIDDK (DP3-DK108245).
• Keywords: Science & Technology; Life Sciences & Biomedicine; FUNCTIONAL CARDIOMYOCYTES; VENTRICULAR CARDIOMYOCYTES; CARDIAC FIBROBLASTS; PROGENITOR CELLS; Research & Experimental Medicine; Medicine, Research & Experimental; IN-VITRO; MESSENGER-RNA; hPSCs; CLINICAL-APPLICATION; Cardiomyocytes; RAT HEARTS; DEFINED FACTORS; MOLECULAR BEACONS
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, General

Abstract

Cardiomyocytes (CMs) derived from human pluripotent stem cells (hPSCs) are considered a most promising option for cell-based cardiac repair. Hence, various protocols have been developed for differentiating hPSCs into CMs. Despite remarkable improvement in the generation of hPSC-CMs, without purification, these protocols can only generate mixed cell populations including undifferentiated hPSCs or non-CMs, which may elicit adverse outcomes. Therefore, one of the major challenges for clinical use of hPSC-CMs is the development of efficient isolation techniques that allow enrichment of hPSC-CMs. In this review, we will discuss diverse strategies that have been developed to enrich hPSC-CMs. We will describe major characteristics of individual hPSC-CM purification methods including their scientific principles, advantages, limitations, and needed improvements. Development of a comprehensive system which can enrich hPSC-CMs will be ultimately useful for cell therapy for diseased hearts, human cardiac disease modeling, cardiac toxicity screening, and cardiac tissue engineering.